ReviewDrug safety2014
Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions.
Review in Drug safety, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Smart Pharmaceutical Monitoring System With Personalized Medication Schedules and Self-Management Programs for Patients With Diabetes: Development and Evaluation Study.Journal of medical Internet research · 2025Article
- A drug prescription recommendation system based on novel DIAKID ontology and extensive semantic rules.Health information science and systems · 2024Article
- Novel deep learning-based transcriptome data analysis for drug-drug interaction prediction with an application in diabetes.BMC bioinformatics · 2021Article
- Potential drug-drug interactions associated with adverse clinical outcomes and abnormal laboratory findings in patients with malaria.Malaria journal · 2020Article
- Osteogenesis of adipose-derived stem cells from patients with glucose metabolism disorders.Molecular medicine (Cambridge, Mass.) · 2020Article
- Extended Intake of Mulberry Leaf Extract Delayed Metformin Elimination via Inhibiting the Organic Cation Transporter 2.Pharmaceutics · 2020Article
- The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.Drugs · 2019Review
- Potential Drug-Drug Interactions in Patients With Urinary Tract Infections: A Contributing Factor in Patient and Medication Safety.Frontiers in pharmacology · 2019Article
- The influence of fibrate initiation on INR and warfarin dose in patients receiving chronic warfarin therapy.Journal of thrombosis and thrombolysis · 2018Article
- DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case-Control Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018Article
- Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review.Journal of transplantation · 2018Review
- Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics.International journal of cardiology · 2017Article
- Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics.Clinical pharmacology and therapeutics · 2016Article
- Clinically and pharmacologically relevant interactions of antidiabetic drugs.Therapeutic advances in endocrinology and metabolism · 2016Review
- Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions.Clinical pharmacology and therapeutics · 2016Review
- Practical combination therapy based on pathophysiology of type 2 diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of type 2 diabetes mellitus is increasing rapidly, as are the associated co-morbidities. Consequently, it has become necessary for a diabetic patient to take multiple medications at the same time to delay progression of the disease. This can put patients at an increased risk of moderate to severe drug interactions, which may threaten patients' life or may deteriorate the quality of their life. Hence, managing drug-drug interactions is the cornerstone of anti-diabetic therapy. Most of the clinically important drug-drug interactions of anti-diabetic agents are related to their metabolic pathways, but drugs that compete for renal excretion or impair renal status can also play an important role. In this review, we have examined the clinical implications and underlying mechanisms of drugs that are likely to alter the pharmacologic response of or cause adverse events with antidiabetic drugs, and we have outlined safe and efficacious treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.